These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2801396)

  • 1. [Pharmacokinetic evaluation of continuous infusion cisplatin].
    Hiura M; Takenawa J; Ryoji O; Taki Y; Hyashi T; Kiriyama T
    Hinyokika Kiyo; 1989 Jun; 35(6):955-61. PubMed ID: 2801396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion.
    Belliveau JF; Posner MR; Ferrari L; Crabtree GW; Cummings FJ; Wiemann MC; O'Leary GP; Griffin H; Phaneuf MA; O'Rourke A
    Cancer Treat Rep; 1986 Oct; 70(10):1215-7. PubMed ID: 3756943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients.
    Forastiere AA; Belliveau JF; Goren MP; Vogel WC; Posner MR; O'Leary GP
    Cancer Res; 1988 Jul; 48(13):3869-74. PubMed ID: 3378222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of high-dose cisplatin administration (relationship between pharmacokinetics and administration schedule)].
    Yamamoto N; Yanagi K; Matuyama H; Shimizu K; Mitsui H; Shimabukuro T; Yamamoto M; Sakatoku J; Fujita T; Matsuoka K
    Hinyokika Kiyo; 1987 Nov; 33(11):1760-5. PubMed ID: 3445857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.
    Vermorken JB; van der Vijgh WJ; Klein I; Hart AA; Gall HE; Pinedo HM
    Cancer Treat Rep; 1984 Mar; 68(3):505-13. PubMed ID: 6538459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC.
    Gouyette A; Ducret JP; Caillé P; Amiel JL; Rouëssé J; Foka M; Carde P; Hayat M; Sancho-Garnier H
    Anticancer Res; 1986; 6(5):1127-32. PubMed ID: 3800320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
    Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
    Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetic analysis of platinum in the continuous CDDP-CBDCA treatment; its relation to the changes of blood biochemistry].
    Chen JT; Hasumi K
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):653-7. PubMed ID: 7717717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis.
    Agostinucci WA; Gannon RH; Golub GR; Martin RS; Schauer PK; Dinonno EB
    Clin Pharm; 1988 Jun; 7(6):454-7. PubMed ID: 3402181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of platinum in cancer patients treated with cisplatin at different doses.
    Fracasso ME; Apostoli P; Benoni G; Bonetti A; Griso C; Leone R
    Drugs Exp Clin Res; 1987; 13(6):367-72. PubMed ID: 3652926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
    Schena M; Barone C; Birocco N; Dongiovanni D; Numico G; Colantonio I; Bertetto O
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
    Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
    Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.
    Kurihara N; Kubota T; Hoshiya Y; Otani Y; Ando N; Kumai K; Kitajima M
    J Surg Oncol; 1996 Jun; 62(2):135-8. PubMed ID: 8649040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic analysis of intra-peritoneal administration of cisplatin].
    Terashima M; Ikeda K; Takagane A; Sasaki N; Abe K; Araya M; Nishizuka S; Yonezawa H; Irinoda T; Nakaya T; Oyama K; Saito K
    Gan To Kagaku Ryoho; 1997 Sep; 24(12):1859-62. PubMed ID: 9382551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity].
    Kitajima K; Fukuoka M; Kobayashi S; Kusunoki Y; Takada M; Negoro S; Matsui K; Sakai N; Ryu S; Takifuji N
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2517-23. PubMed ID: 3039920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
    Chung YS; Yamashita Y; Inoue T; Matsuoka T; Nakata B; Onoda N; Maeda K; Sawada T; Kato Y; Shirasaka T; Sowa M
    Cancer; 1997 Jul; 80(1):1-7. PubMed ID: 9210702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics of plasma and cerebrospinal fluid cisplatin in patients with malignant glioma and metastatic brain tumor after selective intraarterial or intravenous and intracarotid administration of etoposide and cisplatin].
    Nakagawa H; Miyawaki Y; Tokiyoshi K; Tsuruzono K; Yamada M; Kanayama T; Hayakawa T
    No Shinkei Geka; 1994 Jan; 22(1):35-42. PubMed ID: 8295700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.